A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei

Anthony E. Gregory, Barbara M. Judy, Omar Qazi, Carla A. Blumentritt, Katherine A. Brown, Andrew M. Shaw, Alfredo G. Torres, Richard W. Titball

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


Burkholderia mallei are Gram-negative bacteria, responsible for the disease glanders. B. mallei has recently been classified as a Tier 1 agent owing to the fact that this bacterial species can be weaponised for aerosol release, has a high mortality rate and demonstrates multi-drug resistance. Furthermore, there is no licensed vaccine available against this pathogen. Lipopolysaccharide (LPS) has previously been identified as playing an important role in generating host protection against Burkholderia infection. In this study, we present gold nanoparticles (AuNPs) functionalised with a glycoconjugate vaccine against glanders. AuNPs were covalently coupled with one of three different protein carriers (TetHc, Hcp1 and FliC) followed by conjugation to LPS purified from a non-virulent clonal relative, B. thailandensis. Glycoconjugated LPS generated significantly higher antibody titres compared with LPS alone. Further, they improved protection against a lethal inhalation challenge of B. mallei in the murine model of infection.

Original languageEnglish (US)
Pages (from-to)447-456
Number of pages10
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Issue number2
StatePublished - Feb 1 2015


  • Glanders
  • Glycoconjugate
  • Nanoparticles

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • General Materials Science
  • Pharmaceutical Science


Dive into the research topics of 'A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei'. Together they form a unique fingerprint.

Cite this